Mode
Text Size
Log in / Sign up
N/A N=240

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

Breast Cancer Screening · Colon Cancer Screening · Prostate Cancer Screening

Enrolled (actual)
240
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcome: Primary: Shared Decision Making Process Measure — 1.05; 1.20; 2.10 score on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Decision aid (Behavioral)
Age
Adult, Older Adult · 35+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Apr 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Shared Decision Making Process Measure
1.05; 1.20; 2.10
SECONDARY
The 9-item Shared Decision Making Questionnaire
50.5; 56.8; 63.8
SECONDARY
Decisional Conflict Tool (SURE)
49; 51; 67
SECONDARY
Single-Item Measure of Decision Regret
33; 44; 33; 27; 32; 32
SECONDARY
Treatment Choice
39; NA; NA; 8; NA; NA
SECONDARY
Adapted Controlled Preference Scale
33; 33; 45; 10; 19; 5
SECONDARY
Knowledge
43; 58; 62

Summary

The purpose of this retrospective observational study is to evaluate the performance of the Shared Decision Making Process scale in a sample of patients who have received a decision aid about the decision to screen or not screen for breast cancer, colon cancer, prostate cancer, or lung cancer.

Eligibility Criteria

Inclusion Criteria

Breast Cancer group

  • Female sex
  • Between ages of 35-55
  • No previous diagnosis of breast cancer

Colon Cancer Group

  • Between ages of 45-75
  • No previous diagnosis of colon cancer

Prostate Cancer Group

  • Male sex
  • Between ages of 45-74
  • No previous diagnosis of prostate cancer

Lung Cancer Group

  • Between ages of 50-80
  • No previous diagnosis of lung cancer

Exclusion Criteria

Breast Cancer group

  • Unable to confirm primary language is English
  • History of breast cancer
  • Severe cognitive impairment who cannot consent for themselves

Colon Cancer Group

  • Unable to confirm primary language is English
  • History of colon cancer
  • Severe cognitive impairment who cannot consent for themselves

Prostate Cancer Group

  • Unable to confirm primary language is English
  • History of prostate cancer
  • Severe cognitive impairment who cannot consent for themselves

Lung Cancer Group

  • Unable to confirm primary language is English
  • History of lung cancer
  • Severe cognitive impairment who cannot consent for themselves
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04601272). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search